Importance of metabolism in pharmacological studies: Possible in vitro predictability

被引:12
作者
Delaforge, M [1 ]
机构
[1] Univ Paris 05, CNRS, URA400, F-75270 Paris, France
关键词
metabolism; cytochrome P450; cyp; 3A; erythromycin; models;
D O I
10.1016/S0969-8051(98)00063-8
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Metabolic transformation of drug leads to the formation of a large number of secondary compounds. These metabolites may;(a) participate to the elimination of the patent drug, (b) have similar or different therapeutic effects compared to the parent drug (c) exert toxic effects. Cytochromes P450 are the main enzymes involved in the biotransformation of exogenous drugs, leading to oxidized, reduced or peroxidized metabolites. Different isozymes of P450 are present in already all the organs and differ by their affinity for substrate families. P450 3A is the most abundant P450 protein in the adult human liver and is able to transform hundreds of substrates into either drugs or endogenous compounds such as testosterone. Tts catalytic activities are regulated either by induction or by inhibition. Attempts to predict metabolic transformation of a given drug are based on the amount of P450 expressed in heterologous systems, induction, and inhibition experiments and by comparison to classical P450 substrates. Erythromycin metabolism and its P450 effects are used to illustrate the complexity and the consequences of metabolic transformation of a given drug. NUCL MED BIOL 25;8:705-709, 1998. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:705 / 709
页数:5
相关论文
共 15 条
[1]  
BAILEY DG, 1995, CAN J CLIN PHARM, V2, P10
[2]  
BALL SE, 1996, 11 S MICR DRUG OX 21, P32
[3]   PARTICULAR ABILITY OF CYTOCHROMES P450 3A TO FORM INHIBITORY P450-IRON-METABOLITE COMPLEXES UPON METABOLIC OXIDATION OF AMINODRUGS [J].
BENSOUSSAN, C ;
DELAFORGE, M ;
MANSUY, D .
BIOCHEMICAL PHARMACOLOGY, 1995, 49 (05) :591-602
[4]   ASSESSMENT OF LIVER METABOLIC FUNCTION - CLINICAL IMPLICATIONS [J].
BROCKMOLLER, J ;
ROOTS, I .
CLINICAL PHARMACOKINETICS, 1994, 27 (03) :216-248
[5]   Clinically significant drug interactions with cyclosporin - An update [J].
Campana, C ;
Regazzi, MB ;
Buggia, I ;
Molinaro, M .
CLINICAL PHARMACOKINETICS, 1996, 30 (02) :141-179
[6]  
DELAFORGE M, 1995, J PHARMACOL EXP THER, V274, P634
[7]  
Guengerich F. Peter, 1995, P473
[8]   Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes [J].
Iribarne, C ;
Berthou, F ;
Baird, S ;
Dreano, Y ;
Picart, D ;
Bail, JP ;
Beaune, P ;
Menez, JF .
CHEMICAL RESEARCH IN TOXICOLOGY, 1996, 9 (02) :365-373
[9]   EXPRESSION AND INDUCIBILITY OF CYTOCHROME-P450 PROTEINS BELONGING TO FAMILY-2,3 AND FAMILY-4 IN THE RABBIT AORTA [J].
IRIZAR, A ;
IOANNIDES, C .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 213 (03) :916-921
[10]  
KETER TA, 1995, J CLIN PSYCHOPHARM, V15, P387